人类2型糖尿病和肥胖症患者循环中脂联素/β-促胰岛素分泌素水平升高。
Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity.
作者信息
Fu Zhiyao, Berhane Feven, Fite Alemu, Seyoum Berhane, Abou-Samra Abdul B, Zhang Ren
机构信息
1] Center for Molecular Medicine and Genetics, School of Medicine, Wayne State University, Detroit, MI 48201, USA [2].
1] Division of Endocrinology, School of Medicine, Wayne State University, Detroit, MI 48201, USA [2].
出版信息
Sci Rep. 2014 May 23;4:5013. doi: 10.1038/srep05013.
Lipasin (also known as C19ORF80, RIFL, ANGPTL8 and betatrophin) is a newly discovered circulating factor that regulates lipid metabolism and promotes pancreatic β-cell proliferation. Whether circulating levels of lipasin in humans are altered in a) type 2 diabetes; b) obesity and c) the postprandial state, however, is unknown. The current study aimed to compare serum lipasin levels in those who were a) non-diabetic (N=15) or diabetic (BMI- and age-matched; N=14); b) lean or obese (N=53 totally) and c) fasting and 2 hours following a defined meal (N=12). Serum lipasin levels were determined by the enzyme-linked immunosorbent assay. Lipasin levels [mean±SEM] were increased by more than two fold (P<0.001) in the diabetic patients (5.56±0.73 ng/mL) as compared to the control subjects (2.19±0.24 ng/mL). Serum lipasin levels were positively correlated with BMI (rho=0.49, P<0.001), and showed a 35% increase 2 hours following a defined meal (P=0.009). Therefore, lipasin/betatrophin is nutritionally-regulated hepatokine that is increased in human type 2 diabetes and obesity.
脂肪酶（也称为C19ORF80、RIFL、血管生成素样蛋白8和β-促胰岛素分泌素）是一种新发现的循环因子，可调节脂质代谢并促进胰腺β细胞增殖。然而，人类脂肪酶的循环水平在以下情况是否会发生改变尚不清楚：a）2型糖尿病；b）肥胖症；c）餐后状态。本研究旨在比较以下人群的血清脂肪酶水平：a）非糖尿病患者（N = 15）或糖尿病患者（体重指数和年龄匹配；N = 14）；b）瘦人或肥胖者（共N = 53）；c）空腹及特定餐食后2小时（N = 12）。采用酶联免疫吸附测定法测定血清脂肪酶水平。与对照组受试者（2.19±0.24 ng/mL）相比，糖尿病患者（5.56±0.73 ng/mL）的脂肪酶水平[平均值±标准误]增加了两倍多（P<0.001）。血清脂肪酶水平与体重指数呈正相关（rho = 0.49，P<0.001），并且在特定餐食后2小时升高了35%（P = 0.009）。因此，脂肪酶/β-促胰岛素分泌素是一种受营养调节的肝因子，在人类2型糖尿病和肥胖症中升高。
Zotero 插件